| Original language | English |
|---|---|
| Pages (from-to) | 15-17 |
| Number of pages | 3 |
| Journal | Parkinsonism and Related Disorders |
| Volume | 101 |
| DOIs | |
| State | Published - Aug 2022 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Parkinsonism and Related Disorders, Vol. 101, 08.2022, p. 15-17.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Pallidal neuronal activity in multiple system atrophy type P and Parkinson's disease
AU - Milosevic, Luka
AU - Sumarac, Srdjan
AU - Di Luca, Daniel G.
AU - Ramirez-Gomez, Carolina
AU - Hodaie, Mojgan
AU - Hutchison, William D.
AU - Kalia, Suneil K.
AU - Lozano, Andres M.
AU - Lang, Anthony E.
AU - Fasano, Alfonso
N1 - Funding Information: Honoraria, travel funds, consultancy fees, and/or grant support unrelated to this work have been received from the following companies Medtronic (L.M., S.K.K., M.H., W.D.H, A.M.L., A.E.L., A.F.); Boston Scientific (S.K.K., A.M.L., A.F.); St. Jude-Abbott (A.M.L., A.F.); Inbrain Neuroelectronics (S.K.K., A.F.); Insightec (A.M.L.); American Academy of Neurology (A.F.); Abbvie (A.E.L.; A.F.); AFFiRis (A.E.L.), Biogen (A.E.L.); BioAdvance (A.E.L.); BlueRock (A.E.L.), BMS (A.E.L.), Denali (A.E.L.); Janssen (A.E.L.); Lilly (A.E.L.), Retrophin (A.E.L.); Roche (A.E.L.); Sun Pharma (A.E.L.); Sunovion (A.E.L.; A.F.); Sun Pharma (A.E.L.); Chiesi farmaceutici (A.F.); UCB (A.E.L.; A.F.); Ipsen (A.F.); Paladin Lab (A.E.L.; A.F.); Movement Disorders Society (D.G.D.L.; A.F.); MSA Coalition (A.F.); McLaughlin Center (A.F.); Ceregate (A.F.); Gondola (A.F.); Apple (A.F.); Rune Labs (A.F.). Royalties unrelated to this work have been received from Movement Disorders 4 Elsevier (A.E.L.); Saunders (A.E.L.); Parkinson's Disease: non-motor and non-dopaminergic features, Wiley-Blackwell (A.E.L.); Parkinson's disease: a complete guide for patients and families, Johns Hopkins Press (A.E.L.); Neurodegenerative Diseases, Common Movement Disorders Pitfalls, Cambridge University Press (A.E.L.); Springer (A.F.). Grant support has been received from Health Canada, through the Canada Brain Research Fund, an innovative partnership between the Government of Canada (through Health Canada) and Brain Canada, and of the Azrieli Foundation (L.M.); Natural Sciences and Engineering Research Council of Canada (L.M.); New Frontiers; New Frontiers in Research Fund (L.M.); Brain Canada (A.E.L.); Canadian Institute of Health Research (A.E.L.; S.K.), Weston Brain Foundation (S.K.), Michael J Fox Foundation (A.E.L.; S.K.); Porridge for Parkinson's (D.G.D.L.); Corticobasal Degeneration Solutions (A.E.L.); Edmond J Safra Philanthropic Foundation (A.E.L.); the Ontario Brain Institute (A.E.L.); Parkinson Foundation (A.E.L.); Parkinson Canada (A.E.L.); W. Garfield Weston Foundation (A.E.L.). A.F. is the University of Toronto and University Health Network Chair in Neuromodulation. S.S. and C.R.G have no financial disclosures. Funding Information: Honoraria, travel funds, consultancy fees, and/or grant support unrelated to this work have been received from the following companies Medtronic (L.M., S.K.K., M.H., W.D.H, A.M.L., A.E.L., A.F.); Boston Scientific (S.K.K., A.M.L., A.F.); St. Jude-Abbott (A.M.L., A.F.); Inbrain Neuroelectronics (S.K.K., A.F.); Insightec (A.M.L.); American Academy of Neurology (A.F.); Abbvie (A.E.L.; A.F.); AFFiRis (A.E.L.), Biogen (A.E.L.); BioAdvance (A.E.L.); BlueRock (A.E.L.), BMS (A.E.L.), Denali (A.E.L.); Janssen (A.E.L.); Lilly (A.E.L.), Retrophin (A.E.L.); Roche (A.E.L.); Sun Pharma (A.E.L.); Sunovion (A.E.L.; A.F.); Sun Pharma (A.E.L.); Chiesi farmaceutici (A.F.); UCB (A.E.L.; A.F.); Ipsen (A.F.); Paladin Lab (A.E.L.; A.F.); Movement Disorders Society (D.G.D.L.; A.F.); MSA Coalition (A.F.); McLaughlin Center (A.F.); Ceregate (A.F.); Gondola (A.F.); Apple (A.F.); Rune Labs (A.F.). Royalties unrelated to this work have been received from Movement Disorders 4 Elsevier (A.E.L.); Saunders (A.E.L.); Parkinson's Disease: non-motor and non-dopaminergic features, Wiley-Blackwell (A.E.L.); Parkinson's disease: a complete guide for patients and families, Johns Hopkins Press (A.E.L.); Neurodegenerative Diseases, Common Movement Disorders Pitfalls, Cambridge University Press (A.E.L.); Springer (A.F.). Grant support has been received from Health Canada , through the Canada Brain Research Fund , an innovative partnership between the Government of Canada (through Health Canada) and Brain Canada , and of the Azrieli Foundation (L.M.); Natural Sciences and Engineering Research Council of Canada (L.M.); New Frontiers ; New Frontiers in Research Fund (L.M.); Brain Canada (A.E.L.); Canadian Institute of Health Research (A.E.L.; S.K.), Weston Brain Foundation (S.K.), Michael J Fox Foundation (A.E.L.; S.K.); Porridge for Parkinson's (D.G.D.L.); Corticobasal Degeneration Solutions (A.E.L.); Edmond J Safra Philanthropic Foundation (A.E.L.); the Ontario Brain Institute (A.E.L.); Parkinson Foundation (A.E.L.); Parkinson Canada (A.E.L.); W. Garfield Weston Foundation (A.E.L.). A.F. is the University of Toronto and University Health Network Chair in Neuromodulation. S.S. and C.R.G have no financial disclosures.
PY - 2022/8
Y1 - 2022/8
UR - https://www.scopus.com/pages/publications/85132524961
U2 - 10.1016/j.parkreldis.2022.06.007
DO - 10.1016/j.parkreldis.2022.06.007
M3 - Letter
C2 - 35753144
AN - SCOPUS:85132524961
SN - 1353-8020
VL - 101
SP - 15
EP - 17
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
ER -